biologic

Humalog

insulin lispro

Loss of exclusivityNovember 2031projected — 12-year biologic exclusivity estimate
CompanyEli Lilly and Company

Drug detail

Brand nameHumalog
Active ingredientinsulin lispro
Strength300UNITS/3ML (100UNITS/ML)
Dosage formInjection
RouteSubcutaneous
ModalityBiologic
FDA approvalNovember 2019
Marketing statusRx

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Humalog patent cliff — loss of exclusivity November 2031 | CliffBio